Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018075 | 0.84 | DGAT1 (0.38) | DGAT1PDE10ADUT | |
| SCHEMBL6030125 | 0.84 | DGAT1 (0.40) | DGAT1PDE10ADUT | |
| SCHEMBL15823309 | 0.82 | DGAT1 (0.34) | DGAT1PDE10A | |
| SCHEMBL15824847 | 0.81 | DGAT1 (0.34) | DGAT1PDE10A | |
| SCHEMBL20159134 | 0.81 | DGAT1 (0.37) | DGAT1PDE10ADUTKLKB1 | |
| SCHEMBL29492554 | 0.78 | CDK4 (0.49) | — | |
| SCHEMBL1258087 | 0.78 | CDK4 (0.49) | — | |
| SCHEMBL1542347 | 0.77 | NPC1 (0.38) | DGAT1PDE10ACASR | |
| SCHEMBL6028923 | 0.76 | USP2 (0.35) | DGAT1PDE10A | |
| SCHEMBL5730300 | 0.76 | DGAT1 (0.33) | DGAT1PDE10ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | ADRA2A 2924/4885ADRA2B 2961/4885ADRA2C 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.